FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

CL 1 ACL:				of Event Requir nt (Month/Day/ 2022		3. Issuer Name and Ticker or Trading Symbol Oncology Institute, Inc. [ TOI ]					
(Last) C/O THE ONCO 18000 STUDEBA						Relationship of Reporting Person(s) to Issu (Check all applicable)     Director     X Officer (give title below) X	10% Owner		If Amendment, Date of Original Filed (Month/Day/Year)     Individual or Joint/Group Filing (Check Applicable Line)		
(Street) CERRITOS	CA	90703				Chief Financial Officer / Principa	al Financial Of	ficer	X Form filed by One Reporting Person Form filed by More than One Reporting Per		
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
				Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)  2. Date Exert Expiration D. (Month/Day/\(^1\)			ate	Security (Instr. 4) Convers		Conversion or Exercise	se or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	(Instr. 5)			

Explanation of Responses:

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

No securities are beneficially owned.

/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mihir Shah 04/05/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Power of Attorney for: /s/ Mark Hueppelsheuser, Attorney-in-Fact for Mihir Shah SECTION 16

POWER OF ATTORNEY MIHIR SHAH

With respect to holdings of and transactions in securities issued by The Oncology Institute, Inc. (the "Company"), the undersigned hereby constitute, prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commiss:

- 2. execute for and on behalf of the undersigned, Forms 3, 4, and 5 in accordance with Section 16 of the Securities Exchange Act of 1934, as amu
- 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such FG
- 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of bene

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever: The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assumed that the power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respectively.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of April, 2022.

/s/ Mihir Shah Name: Mihir Shah